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Antifungal activityAbstract A new series of 5-amino-6-(benzo[d]thiazol-2-yl)-2-(2-(substitutedbenzylidene)hydrazi-
nyl)-7-(4-chlorophenyl)pyrido[2,3-d]pyrimidin-4(3H)-one derivatives (7a–k) were synthesized. All
the newly synthesized compounds were screened for their in vitro antibacterial activity, against
Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa and
Streptococcus pyogenes and for antifungal activity against Aspergillus ﬂavus, Aspergillus fumigatus,
Candida albicans, Penicillium marneffei and Mucor. Compounds 7b, 7e, 7f, 7g, 7h and 7j showed
excellent in vitro antibacterial activity and antifungal activity than the standard drugs. All the com-
pounds were characterized by IR, 1H NMR, 13C NMR, LCMS mass and C, H, N analyses.
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Pyrimidine which is an integral part of DNA and RNA
imparts diverse pharmacological properties as effectivebactericide and fungicide (Williams and Cline, 1936; Maddila
and Jonnalagadda, 2012a,b). Many pyrimidine derivatives
are known to exhibit analgesic (Regnier et al., 1972), antihy-
pertensive (Winter et al., 1962), anti-tumour (Suguira et al.,
1973), antimalarial (Brown and Evans, 1985), antioxidant (Ste-
fani et al., 2006), antimitotic (Mayer et al., 1999), and anti-
HIV activities (Okabe et al., 1991). Some dihydropyrimidines
(DHPM) have emerged as integral backbones of calcium chan-
nel blockers, antihypertensive agents, adrenergic and neuro-
peptide antagonists (Pasha et al., 2005). Several alkaloids
containing dihydropyrimidine isolated from marine sources
such as batzelladine alkaloids are reported to be potent
HIV-gp-120-CD4 inhibitors (Kappe et al., 2000; Kappe
et al., 2000; Patil et al., 1995).
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tion with other heterocyclics, pyrimidines are known to play a
crucial role in several processes of chemical and pharmacolog-
ical importance as therapeutics in clinical applications. A liter-
ature survey reveals that thiazole derivatives of pyrimidine
have received much attention in recent years, due to their efﬁ-
cacy as analgesic, anti-inﬂammatory, ulcerogenic (Hafez and
El-Gazzar, 2008), antifungal (Maddila et al., 2011a,b, 2016),
antitubercular (Kapustina et al., 1991), antimalarial (Rosow-
sky et al., 1973), antitumour (Sasaki et al., 2003), cytotoxic
(Suh et al., 2000), and anticancer agents (Skibo et al., 2002).
In the view of having a wide scope to ﬁnd new potentially
active agents, we have synthesized a new series of benzothiazole
pyrimidine derivatives (7a–k) which is an extension of our
previous reported work on biological studies of novel 2-(4-sub-
stitutedbenzylthio)-5-amino-6-(benzo[d]thiazol-2-yl)-7-(4-chlo-
rophenyl)pyrido[2,3-d]-pyrimidin-4(3H)-one (Maddila et al.,
2011). All the new compounds were characterized by elemental
and spectral analyses and screened for their antibacterial and
anti- fungal abilities.2. Results and discussion
2.1. Chemistry
For the synthesis of the new materials, initially,
2-(benzo[d]thiazol-2-yl)acetonitrile (1) was treated with
cyanoacetic acid in the presence of acetic anhydride to give
their corresponding 2-(benzo[d]thiazol-2-yl)-3-oxopentane
dinitrile (2). Compound 2 was reacted with p-chlorobenzalde-
hyde in the presence of piperidine to obtain 2-(benzo[d]thiazol-
2-yl)-3-(4-chlorophenyl)-acrylonitrile (3) (Saito et al., 1983).
Compound 3 by cyclization with 6-aminothiouracil in the pres-
ence of few drops of piperidine, was converted into 5-amino-
6-(benzo[d]thiazol-2-yl)-7-(4-chlorophenyl)-2-thioxo-2,3-dihy-
dropyrido[2,3-d]pyrimidin-4(1H)-one (4) with good yield.
Compound 4 was treated with benzyl bromide in the presence
of K2CO3 and DMF medium to give its benzylthio derivative
(5) in good yield (Maddila et al., 2011b).
The benzylthio compound was successfully reacted with
hydrazine hydrate to afford its hydrazinyl derivative (6). The
hydrazinyl derivative was condensed with a range of selected
substituted aldehydes in the presence of DMF solvent, to yield
a new series of corresponding Schiff bases in good yields
(7ak) (Scheme 1).
All the newly synthesized compounds gave moderate to high
yields. Products were puriﬁed and characterized by various
spectroscopic techniques. The IR spectra of compounds
(7a–k) showed characteristic absorption bands at 3460–
3387 cm1, 1679–1609 cm1, 1623–1561, and 1548–1520 cm1
corresponding to the N–H2str, C‚Ostr, C‚Nstr and C‚Cstr
functions in the structures. The 1H NMR spectra showed peaks
in the range of d 6.09–6.29 for NH2, d 8.01–8.71 for N‚CH, d
9.91–10.05 for hydrazinyl NH and d 10.17–10.25 for pyrimidine
NH. The mass spectrum of all the compounds showed a
molecular ion peak at M+, at M+H corresponding to its
molecular formula, which conﬁrmed its chemical structure.
IR, 1H NMR, LCMS mass spectra and elemental analysis con-
ﬁrmed the structure of various novel 5-amino-6-(benzo[d]
thiazol-2-yl)-2-(2-(substitutedbenzylidene)hydrazinyl)-7-(4-chlorophenyl)pyrido[2,3-d]pyrimidin-4(3H)-one derivatives
(7a–k).
3. Pharmacological assay
3.1. Antimicrobial activity
All the compounds were screened for their antibacterial activ-
ity against Staphylococcus aureus, Escherichia coli, Klebsiella
pneumoniae, Pseudomonas aeruginosa and Streptococcus pyog-
enes and antifungal activity against Aspergillus ﬂavus, Aspergil-
lus fumigatus, Candida albicans, Penicillium marneffei and
Mucor. Compounds 7b–k with various substituents in the aro-
matic ring will give an insight into the steric and electronic ef-
fects on the biological activity.
3.2. Evaluation of antibacterial activity
The in vitro antibacterial activity of the compounds was tested
in nutrient broth for bacteria by the twofold serial dilution
method (Vincent and Vincent, 1944). The test compounds were
dissolved in dimethyl sulphoxide (DMSO) to obtain 1 mg/ml
stock solutions. Seeded broth (broth containing microbial
spores) were prepared in NB from 24 h old bacterial cultures
on nutrient agar at 37 ± 1 C. The colony forming units
(cfu) of the seeded broth were determined by the plating tech-
nique and adjusted in the range of 104–105 cfu/ml. The anti-
bacterial assay was performed at pH 7.4 ± 0.2, with the ﬁnal
inoculum size of 105 cfu/ml. 0.20 ml of the solution of the test
compound was added to 1.80 ml of seeded broth to form the
ﬁrst dilution. One millilitre of it was diluted with an equal vol-
ume of the seeded broth to give the second dilution. The dilu-
tion was continued in one ml increments to obtain six such
dilutions. A set of assay tubes containing seeded broth were
kept as controls and likewise solvent controls were also run
simultaneously. The tubes were incubated in biochemical oxy-
gen demand (BOD) incubators at 37 ± 1 C for bacteria. The
minimum inhibiting concentrations (MICs) were recorded by
visual observations after 24 h. Ciproﬂoxacin was used as a
standard for the antibacterial study.
For evaluating the antibacterial activity ciproﬂoxacin was
used as the standard drug. The observed minimum inhibitory
concentrations (MICs) are given in Table 1. In general, all
the compounds exerted a modest to good antibacterial activity
in vitro against the tested organisms. Compound 7a without
any substituent in the aryl moiety exhibited antibacterial activ-
ity in vitro at 100 lg ml1 against P. aeruginosa, but its anti-
bacterial activity against the other tested organisms was only
at 200 lg ml1. However 7b, in which the hydrogen at the para
position of the aryl moiety is replaced by chlorine, showed a
very good activity against all the tested organisms in the range
of 25–50 lg ml1. Compound 7c, which had the chlorine in the
ortho position, exhibited similar activity as 7b. Undeniably the
compounds 7b–k, bearing a substituent in the aryl group, are
more active than the parent compound, 7a. Compound 7a
and its isopropyl analogue 7k have the similar moderate activ-
ity against K. pneumoniae. However, 7k showed higher activity
than 7a against all the other tested organisms. Interestingly, 7f
with a nitro substituent, 7i with an amide and 7g with ﬂuorine
all in the para position, exhibited higher activity relative to
Ciproﬂoxacin.
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Table 1 In vitro antibacterial activity of compounds (7a–k).
Compound Minimum inhibitory concentration (MIC) in lg ml1
S. aureus E. coli K. pneumoniae P. aeruginosa S. pyogenes
7a 200 200 200 100 200
7b 25 25 50 50 25
7c 25 25 50 50 25
7d 50 50 100 100 100
7e 50 50 100 50 50
7f 12.5 25 25 25 12.5
7g 12.5 12.5 12.5 12.5 12.5
7h 100 100 100 100 50
7i 25 12.5 12.5 25 12.5
7j 50 100 50 25 100
7k 100 50 200 100 50
Ciproﬂoxacin 25 25 50 25 12.5
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The in vitro antifungal activity of the compounds was exam-
ined in Sabouraud’s dextrose broth for fungi by the two-fold
serial dilution method (Vincent and Vincent, 1944). The test
compounds were dissolved in dimethyl sulphoxide (DMSO)
to obtain 1 mg/ml stock solutions. Seeded broth (broth con-
taining microbial spores) was prepared by suspending 24 h to
7-day old Sabouraud’s agar slant cultures in SDB. The colony
forming units (cfu) of the seeded broth were determined by the
plating technique and adjusted in the range of 104–105 cfu/ml.
For antifungal assay the ﬁnal inoculum size was 1.1–
1.5 · 102 cfu/ml. Testing was carried out by the same proce-
dure as done for antibacterial studies except the temperature
which was maintained at 28 ± 1 C for about 72–96 h of incu-
bation. Clotrimazole was used as a standard for the antifungal
study.
For evaluating the antifungal activity clotrimazole was used
as the standard drug. The observed minimum inhibitory con-
centrations (MICs) are given in Table 2. 7a showed no activity
against A. fumigates or C. albicans even at 200 lg ml1 concen-
trations. However, it exhibited antifungal activity against all
the other tested fungi in the range of 100–200 lg ml1. Com-
pounds 7b–k which have substituents in the 4-aryl group were
more active than the parent compound, 7a against all the
tested fungi. The o-chloro compound, 7c showed less activity
compared to p-chloro compound, 7b against A. fumigates
and P. marneffei. However, against all the tested fungi, both
7b and 7c displayed good activity. Against all the tested organ-
isms, compounds 7f, 7g and 7i exhibited higher activity than
the standard drug Clotrimazole.
3.4. Inﬂuence of aromatic substituent
The results suggest that the antibacterial and antifungal activ-
ities are distinctly inﬂuenced by the aromatic substituents.
Compounds 7b, 7c, 7f, 7g and 7i with electron-withdrawing
substituents in the aromatic ring, displayed greater antibacte-
rial activity than the other six compounds against all the tested
organisms. Furthermore, compounds 7f, 7g and 7i showed
greater antifungal activity relating to all the other compounds
against all the tested organisms. The aromatic substituents inTable 2 In vitro antifungal activity of compounds (7a–k).
Compound Minimum inhibitory concentration (MIC) in
A. ﬂavus A. fumigatus
7a 100 –
7b 25 50
7c 25 100
7d 100 200
7e 100 50
7f 12.5 12.5
7 g 12.5 12.5
7 h 100 200
7i 25 12.5
7j 50 100
7 k 100 50
Clotrimazole 25 25
–, no inhibition even at a higher concentration of 200 lg ml1.7b, 7c, 7f, 7g and 7i had positive values25 for the Hammett sub-
stituent constant, rp.
4. Experimental
All reagents and solvents were purchased and used without
further puriﬁcation. Melting points determined on a Fisher–
Johns melting point apparatus were uncorrected. Crude prod-
ucts were puriﬁed by column chromatography on silica gel of
60–120 mesh. IR spectra were obtained on a Perkin Elmer BX
series FT-IR 5000 spectrometer using KBr pellet. The 1H
NMR spectra were recorded on a Varian 400 MHz spectrom-
eter for 1H NMR. Carbon nuclear magnetic resonance (13C
NMR) spectra were recorded on a Bruker 100 MHz spectrom-
eter. LCMS Mass spectra were recorded on a MASPEC low
resolution mass spectrometer operating at 70 eV.
4.1. 2-(Benzo[d]thiazol-2-yl)-3-oxopentanedinitrile (2)
The mixture of cyanoacetic acid (0.01 mol) and acetic anhy-
dride (15 mL) was heated on a water bath for 5 min and 2-
(benzo[d]thiazol-2-yl)acetonitrile (1) (0.01 mol) was added.
The reaction mixture was reﬂuxed for 20 min at 85–95 C left
to cool, and the formed solid was ﬁltered off, dried and recrys-
tallized from ethanol to afford 1.69 g (70%) of 2; mp 275 C;
brown crystals; IR (t cm1, KBr): 2185, 2199 (2CN), 1700
(CO). 1H NMR (DMSO-d6) d 6.67-7.50 (m, 4H, Ar-H), 5.10
(s, 1H, CH), 4.52 (s, 2H, CH2);
13C NMR (100 MHz,
DMSO-d6): d 184.2, 162.1, 148.3, 134.2, 123.4, 122.1, 120.3,
120.1, 117.2, 116.5, 48.2, 34.4; LCMS: (m/z,%): 241 [M+].
Anal. Calcd. for C12H7N3OS: C, 59.74; H, 2.92; N, 17.42.
Found: C, 59.92; H, 2.97; N, 17.53.
4.2. 2-(Benzo[d]thiazol-2-yl)-3-(4-chlorophenyl)-acrylonitrile
(3)
To a solution of 2 (0.01 mol) and p-chlorobenzaldehyde
(0.01 mol) in ethanol (20 mL), a few drops of piperidine were
added. The reaction mixture was reﬂuxed for 4 h, then left to
cool. The precipitate formed was ﬁltered off, washed, and
recrystallized by ethanol to afford 2.11 g (71%) of 3; mp
148–150 C; yellow powder; IR (t cm1, KBr): 3119 (NH),lg ml1
C. albicans P. marneﬀei Mucor
– 200 200
50 25 50
50 50 50
50 50 100
50 50 100
25 25 12.5
12.5 12.5 12.5
100 100 200
25 12.5 25
50 50 50
100 100 100
50 25 50
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vinylic H); 13C NMR (100 MHz, DMSO-d6): d 164.5, 152.5,
150.6, 148.2, 134.3, 133.2, 132.8, 128.3, 127.6, 124.5, 123.7,
120.9, 117.3, 109.2; LCMS: (m/z,%): 298 [M+ H]. Anal.
Calcd. for C16H9ClN2S: C, 64.75; H, 3.06; N, 9.44. Found:
C, 64.84; H, 3.17; N, 9.51.
4.3. 5-Amino-6-(benzo[d]thiazol-2-yl)-7-(4-chlorophenyl)-2-
thioxo-2,3-dihydropyrido-[2,3-d]-pyrimidin-4(1H)-one (4)
To a mixture of 3 (0.01 mol) and 6-aminothiouracil (0.01 mol)
in ethanol (15 mL), a catalytic amount of piperidine (few
drops) was added. The reaction mixture was reﬂuxed for 6 h,
allowed to cool and poured into ice cold water. The precipitate
obtained was ﬁltered off, dried and recrystallized from ethanol.
Pale yellow powder; Yield 62%; mp 230–231 C; IR (t cm1,
KBr): 3402, 3389 (NH2), 3141 (NH), 1698 (CO), 1221
(C‚S). 1H NMR (DMSO-d6): d 13.59 (s, 1H, NH), 13.51 (s,
1H, NH), 7.32-8.49 (m, 8H, Ar-H), 6.22 (s, 2H, NH2);
13C
NMR (100 MHz, DMSO-d6): d 172.2, 162.0, 156.6, 154.2,
152.6, 150.7, 148.3, 135.0, 133.5, 131.5, 128.3, 128.1, 124.4,
123.6, 120.3, 120.0, 109.2, 92.3; LCMS: (m/z,%): 438 [M+].
Anal. Calcd. for C20H12ClN5OS2: C, 54.84; H, 2.76; N,
15.99. Found: C, 54.94; H, 2.82; N, 16.04.
4.4. 5-Amino-6-(benzo[d]thiazol-2-yl)-2-(benzylthio)-7-(4-
chlorophenyl)pyrido[2,3-d] pyrimidin–4(3H)-one (5)
An ice cold solution of cyclic compound of 4 (0.01 mol) in
DMF (15 ml), potassium carbonate (0.03 mol) and benzyl bro-
mide (0.02 mol) was taken in a 250 ml round bottomed ﬂask
equipped with magnetic stirrer and stirred for 3 h. The residual
portion was poured on crushed ice, neutralized with dilute acid
and the product obtained (5) was collected by ﬁltration.
Pale yellow solid; Yield 69%; mp 196–198 C; IR (t cm1,
KBr): 3402-3389 (NH2), 3141 (NH), 1698 (CO) cm
1; 1H
NMR (400 MHz, DMSO-d6) d 13.58 (s, 1H, NH), 7.32-8.49
(m, 13H, Ar-H), 6.23 (s, 2H, NH2), 4.10 (s, 2H, CH2);
13C
NMR (100 MHz, DMSO-d6): d 162.1, 160.2, 156.8, 154.2,
152.6, 150.9, 150.1, 149.3, 138.2, 133.4, 133.0, 131.4, 128.5,
128.2, 127.7, 127.3, 126.7, 126.2, 124.4, 123.6, 122.1, 109.2,
34.5; LCMS: (m/z) 528 [M+ H]. Anal. Calcd. for
C27H18ClN5OS2: C, 61.41; H, 3.44; N, 13.26. Found: C,
61.55; H, 3.53; N, 13.39.
4.5. 5-Amino-6-(benzo[d]thiazol-2-yl)-7-chloro-2-
hydrazinylpyrido[2,3-d]pyrimidin-4(3H) one (6)
A mixture of compound 6 (0.01 mol) and hydrazine hydrate
85% (0.03 mol) in 2-propanol (25 ml) was reﬂuxed for 3 h.
After cooling, the precipitate was ﬁltered off, recrystallized
from alcohol, and dried in vacuum over P2O5 to give a brown
solid.
Yield: 80%; mp 152–154 C; IR (t cm1, KBr): 3325 (NH–
NH2), 1738 (C‚O), 1618 (C‚N), 1532 (C‚C) cm
1; 1H
NMR (400 MHz, DMSO-d6) d 10.27 (s, 1H, NH–pyrimidine),
8.2–8.3 (d, 2H, NH2–hydrazinyl), 8–8.2 (t, 1H, NH–hydrazi-
nyl), 7.51–7.98 (m, 4H, Ar–H), 6.11 (s, 2H, NH2),;
13C
NMR (100 MHz, DMSO-d6): d 170.2, 162.1, 156.6, 154.3,
153.6, 151.5, 149.9, 133.6, 132.2, 131.7, 128.5, 128.1, 126.3,
126.1, 124.3, 121.2, 120.6, 117.1, 109.5; LCMS: (m/z) 360(M +H, 100%). Anal. Calcd. for C14H10ClN7OS: C, 46.73;
H, 2.80; N, 27.25. Found: C, 46.61; H, 2.87; N, 27.33.c
4.6. 5-amino-6-(benzo[d]thiazol-2-yl)-2-(2-
(substitutedbenzylidene)hydrazinyl)-7-(4-
chlorophenyl)pyrido[2,3-d]pyrimidin-4(3H)-one derivatives
(7a–k)
A mixture of hydrazinyl compound 6 (0.01 mol) and the
appropriate aldehyde (0.03 mol) in DMF (20 ml) was stirred
at room temperature for 10 h. After the reaction time, the solu-
tion was evaporated under reduced pressure and the residue
was triturated with water to yield corresponding pure com-
pounds, which were collected by ﬁltration and recrystallized
from alcohol.
4.6.1. 5-Amino-6-(benzo[d]thiazol-2-yl)-2-(2-
benzylidenehydrazinyl)-7-(4-chlorophenyl)pyrido[2,3-
d]pyrimidin-4(3H)-one (7a)
Yield: 76%; mp 254–256 C; IR (t cm1, KBr): 3402 (NH2),
1665 (C‚O), 1578 (C‚N), 1523 (C‚C), cm1; 1H NMR
(400 MHz, DMSO-d6): d 10.19 (s, 1H, NH–pyrimidine), 9.98
(s, 1H, NH–hydrazinyl), 8.15–8.42 (m, 4H, Ar–H), 8.03 (s,
1H, N‚CH), 7.45–7.79 (m, 9H, Ar–H), 6.09 (s, 2H, NH2);
13C NMR (100 MHz, DMSO-d6): d 171.0, 162.6, 159.2,
155.4, 154.2, 153.1, 151.1, 147.1, 135.3, 134.5, 133.8, 133.1,
131.7, 130.5, 130.2, 129.9, 129.3, 126.2, 125.8, 122.9, 122.2,
119.1, 109.3; LCMS: (m/z) 524 (M+ H, 100%). Anal. Calcd.
for C27H18ClN7OS: C, 67.19; H, 5.65; N, 11.09. Found: C,
67.24; H, 5.59; N, 11.17.
4.6.2. 5-Amino-6-(benzo[d]thiazol-2-yl)-2-(2-(4-
chlorobenzylidene)hydrazinyl)-7-(4-chlorophenyl)pyrido[2,3-
d]pyrimidin-4(3H)-one (7b)
Yield: 85%; mp 201–203 C; IR (t cm1, KBr): 3460 (NH2),
1609 (C‚O), 1594 (C‚N), 1547 (C‚C), 712 (C–Cl) cm1;
1H NMR (400 MHz, DMSO-d6): d 10.20 (s, 1H, NH–pyrimi-
dine), 10.01 (s, 1H, NH–hydrazinyl), 8.11–8.43 (m, 4H, Ar–
H), 8.05 (s, 1H, N‚CH), 7.48–7.75 (m, 8H, Ar–H), 6.21 (s,
2H, NH2);
13C NMR (100 MHz, DMSO-d6): d 171.1, 162.7,
159.3, 155.4, 154.3, 153.2, 151.1, 147.1, 137.3, 135.3, 134.6,
133.1, 132.6, 131.6, 130.5, 129.9, 129.9, 126.2, 125.8, 122.8,
122.2, 119.1, 109.2; LCMS: (m/z) 558 (M+ H, 100%). Anal.
Calcd. for C27H17Cl2N7OS: C, 65.65; H, 5.70; N, 10.56.
Found: C, 65.73; H, 5.61; N, 10.48.
4.6.3. 5-Amino-6-(benzo[d]thiazol-2-yl)-2-(2-(2-
chlorobenzylidene)hydrazinyl)-7-(4-chloro phenyl)pyrido[2,3-
d]pyrimidin-4(3H)-one (7c)
Yield: 69%; mp 191–192 C; IR (t cm1, KBr): 3387 (NH2),
1648 (C‚O), 1575 (C‚N), 1538 (C‚C), 715 (C–Cl) cm1;
1H NMR (400 MHz, DMSO-d6): d 10.21 (s, 1H, NH–pyrimi-
dine), 10.05 (s, 1H, NH–hydrazinyl), 8.10–8.45 (m, 4H, Ar–
H), 8.71 (s, 1H, N‚CH), 7.39–7.75 (m, 8H, Ar–H), 6.19 (s,
2H, NH2);
13C NMR (100 MHz, DMSO-d6): d 171.2, 162.8,
159.3, 155.4, 154.2, 153.1, 151.1, 147.1, 135.3, 134.6, 133.6,
133.1, 132.6, 131.6, 130.3, 129.9, 129.7, 127.9, 126.3, 125.8,
122.8, 122.3, 119.1, 109.3; LCMS: (m/z) 558 (M+H,
100%). Anal. Calcd. for C27H17Cl2N7OS: C, 68.62; H, 6.31;
N, 10.56. Found: C, 68.55; H, 6.25; N, 10.63.
686 S. Maddila et al.4.6.4. 5-Amino-6-(benzo[d]thiazol-2-yl)-2-(2-(4-
methylbenzylidene)hydrazinyl)-7-(4-chloro -phenyl)pyrido[2,3-
d]pyrimidin-4(3H)-one (7d)
Yield: 87%; mp 235 C; IR (t cm1, KBr): 3412 (NH2), 1660
(C‚O), 1569 (C‚N), 1528 (C‚C), cm1; 1H NMR
(400 MHz, DMSO-d6): d 10.17 (s, 1H, NH–pyrimidine), 9.91
(s, 1H, NH–hydrazinyl), 8.15–8.42 (m, 4H, Ar–H), 8.01 (s,
1H, N‚CH), 7.26–7.68 (m, 8H, Ar–H), 6.20 (s, 2H, NH2),
2.21 (s, 3H, CH3);
13C NMR (100 MHz, DMSO-d6): d 171.1,
162.6, 159.3, 155.4, 154.2, 153.1, 151.0, 147.1, 139.9, 135.2,
134.5, 133.1, 131.2, 130.3, 130.2 130.1, 129.8, 126.3, 125.7,
122.8, 122.3, 119.1, 109.2, 23.8; LCMS: (m/z) 538 (M+H,
100%). Anal. Calcd. for C28H20ClN7OS: C, 69.04; H, 6.52;
N, 10.06. Found: C, 70.07; H, 6.44; N, 10.16.4.6.5. 5-Amino-6-(benzo[d]thiazol-2-yl)-2-(2-(4-
methoxybenzylidene)hydrazinyl)-7-(4-chloro-
phenyl)pyrido[2,3-d]pyrimidin-4(3H)-one (7e)
Yield: 84%; mp 209–211 C; IR (t cm1, KBr): 3452 (NH2),
1648 (C‚O), 1576 (C‚N), 1541 (C‚C), 1210 (C–O–C) cm
1; 1H NMR (400 MHz, DMSO-d6): d 10.19 (s, 1H,
NH–pyrimidine), 10.03 (s, 1H, NH–hydrazinyl), 8.12–8.42
(m, 4H, Ar–H), 8.06 (s, 1H, N‚CH), 7.01–7.78 (m, 8H,
Ar–H), 6.23 (s, 2H, NH2), 3.78 (s, 3H, OCH3);
13C NMR
(100 MHz, DMSO-d6): d 171.2, 165.41 162.7, 159.3, 155.4,
154.2, 153.1, 151.1, 147.1, 135.3, 134.6, 133.1, 131.4, 130.8,
129.8, 127.2, 126.3, 125.7, 122.9, 122.2, 119.1, 113.7, 109.3,
57.6; LCMS: (m/z) 553 (M+, 100%). Anal. Calcd. for
C28H20ClN7O2S: C, 65.65; H, 5.70; N, 10.56. Found: C,
65.73; H, 5.79; N, 10.61.4.6.6. 5-Amino-6-(benzo[d]thiazol-2-yl)-2-(2-(4-
ﬂuorobenzylidene)hydrazinyl)-7-(4-chloro phenyl)pyrido[2,3-
d]pyrimidin-4(3H)-one (7f)
Yield: 91%; mp 186–187 C; IR (t cm1, KBr): 3438 (NH2),
1650 (C‚O), 1606 (C‚N), 1548 (C‚C), 1010 (C–F) cm1;
1H NMR (400 MHz, DMSO-d6): d 10.21 (s, 1H, NH–pyrimi-
dine), 10.01 (s, 1H, NH–hydrazinyl), 8.16–8.38 (m, 4H, Ar–
H), 8.06 (s, 1H, N‚CH), 7.40–7.77 (m, 8H, Ar–H), 6.24 (s,
2H, NH2);
13C NMR (100 MHz, DMSO-d6): d 171.3, 167.2,
162.9, 159.8, 155.4, 154.3, 153.1, 151.1, 147.2, 135.4, 134.7,
133.2, 131.7, 130.5, 130.4, 129.9, 126.3, 125.9, 122.9, 122.3,
119.1, 116.3, 109.4; LCMS: (m/z) 542 (M+ H, 100%). Anal.
Calcd. for C27H17ClFN7OS: C, 64.28; H, 5.75; N, 9.98. Found:
C, 64.39; H, 5.66; N, 10.07.4.6.7. 5-Amino-6-(benzo[d]thiazol-2-yl)-2-(2-(4-
nitrobenzylidene)hydrazinyl)-7-(4-chloro phenyl)pyrido[2,3-
d]pyrimidin-4(3H)-one (7g)
Yield: 79%; mp 224–226 C; IR (t cm1, KBr): 3408 (NH2),
1669 (C‚O), 1574 (C‚N), 1520 (C‚C), cm1; 1H NMR
(400 MHz, DMSO-d6): d 10.25 (s, 1H, NH–pyrimidine),
10.05 (s, 1H, NH–hydrazinyl), 8.12–8.40 (m, 4H, Ar–H),
8.08 (s, 1H, N‚CH), 7.48–7.56 (m, 8H, Ar–H), 6.29 (s, 2H,
NH2);
13C NMR (100 MHz, DMSO-d6): d 171.3, 163.0,
159.4, 155.5, 154.3, 153.2, 151.2, 149.7, 147.2, 141.1, 135.4,
134.7, 133.2, 131.6, 130.4, 129.9, 126.3, 115.2, 122.2, 122.3,
121.3, 119.1, 109.4; LCMS: (m/z) 569 (M+ H, 100%). Anal.
Calcd. for C27H17ClN8O3S: C, 67.11; H, 6.35; N, 9.78. Found:
C, 66.98; H, 6.27; N, 9.83.4.6.8. 5-Amino-6-(benzo[d]thiazol-2-yl)-2-(2-(2,4-
dimethylbenzylidene)hydrazinyl)-7-(4-
chlorophenyl)pyrido[2,3-d]pyrimidin-4(3H)-one (7h)
Yield: 85%; mp 168–170 C; IR (t cm1, KBr): 3430 (NH2),
1665 (C‚O), 1580 (C‚N), 1532 (C‚C), cm1; 1H NMR
(400 MHz, DMSO-d6): d 10.19 (s, 1H, NH–pyrimidine), 9.98
(s, 1H, NH–hydrazinyl), 8.11–8.40 (m, 4H, Ar–H), 8.59 (s,
1H, N‚CH), 7.03–7.55 (m, 7H, Ar–H), 6.18 (s, 2H, NH2),
2.41 (s, 3H, CH3), 2.28 (s, 3H, CH3);
13C NMR (100 MHz,
DMSO-d6): d 171.1, 162.6, 159.3, 155.4, 154.2, 153.1, 151.0,
147.1, 141.2, 138.8, 135.3, 134.6, 133.2, 131.8, 133.4, 129.9,
129.7, 126.9, 126.3, 125.7, 124.4, 122.8, 122.2, 119.1, 109.1,
25.0, 17.4; LCMS: (m/z) 551 (M+, 100%). Anal. Calcd. for
C29H22ClN7OS: C, 67.56; H, 6.53; N, 9.55. Found: C, 67.48;
H, 6.59; N, 9.63.
4.6.9. 5-Amino-6-(benzo[d]thiazol-2-yl)-2-(2-(4-
aminobenzylidene)hydrazinyl)-7-(4-chloro phenyl)pyrido[2,3-
d]pyrimidin-4(3H)-one (7i)
Yield: 77%; mp 221–223 C; IR (t cm1, KBr): 3450 (NH2),
1679 (C‚O), 1623 (C‚N), 1528 (C‚C), cm1; 1H NMR
(400 MHz, DMSO-d6): d 10.21 (s, 1H, NH–pyrimidine),
10.02 (s, 1H, NH–hydrazinyl), 8.14–8.40 (m, 4H, Ar–H),
8.04 (s, 1H, N‚CH), 6.81–7.52 (m, 8H, Ar–H), 6.27 (s, 2H,
NH2), 5.47 (s, 2H, NH2);
13C NMR (100 MHz, DMSO-d6):
d 171.3, 162.9, 159.3, 155.4, 154.3, 153.2, 151.0, 151.0, 147.2,
135.3, 134.6, 133.2, 131.4, 130.4, 129.9, 126.3, 125.8, 124.4,
122.9, 122.3, 119.1, 118.3, 109.4; LCMS: (m/z) 539 (M+ H,
100%). Anal. Calcd. for C27H19ClN8OS: C, 68.60; H, 6.32;
N, 10.32. Found: C, 68.73; H, 6.41; N, 10.25.
4.6.10. 5-Amino-6-(benzo[d]thiazol-2-yl)-2-(2-(4-
ethylbenzylidene)hydrazinyl)-7-(4-chloro phenyl)pyrido[2,3-
d]pyrimidin-4(3H)-one (7j)
Yield: 69%; mp 218–219 C; IR (t cm1, KBr): 3432 (NH2),
1629 (C‚O), 1561 (C‚N), 1543 (C‚C) cm1; 1H NMR
(400 MHz, DMSO-d6): d 10.18 (s, 1H, NH–pyrimidine), 9.97
(s, 1H, NH–hydrazinyl), 8.12–8.40 (m, 4H, Ar–H), 8.02 (s,
1H, N‚CH), 7.31–7.71 (m, 8H, Ar–H), 6.22 (s, 2H, NH2),
2.52 (q, 2H, CH2), 1.27 (t, J= 7.2 Hz, 3H, CH3);
13C NMR
(100 MHz, DMSO-d6): d 171.2, 162.7, 159.3, 155.4, 154.2,
153.2, 151.1, 145.1, 142.1, 135.3, 134.6, 133.1, 132.1, 130.3,
129.8, 129.4, 128.3, 126.3, 125.7, 122.6, 122.2, 119.1, 109.2,
31.3, 15.1; LCMS: (m/z) 552 (M+H, 100%). Anal. Calcd.
for C29H22ClN7OS: C, 67.11; H, 6.34; N, 9.79. Found: C,
67.23; H, 6.42; N, 9.87.
4.6.11. 5-Amino-6-(benzo[d]thiazol-2-yl)-2-(2-(4-
isopropylbenzylidene)hydrazinyl)-7-(4-chloro
phenyl)pyrido[2,3-d]pyrimidin-4(3H)-one (7k)
Yield: 78%; mp 206–208 C; IR (t cm1, KBr): 3421 (NH2),
1650 (C‚O), 1574 (C‚N), 1523 (C‚C), cm1; 1H NMR
(400 MHz, DMSO-d6): d 10.18 (s, 1H, NH–pyrimidine), 9.96
(s, 1H, NH–hydrazinyl), 8.10–8.44 (m, 4H, Ar–H), 8.04 (s,
1H, N‚CH), 7.33–7.71 (m, 8H, Ar–H), 6.20 (s, 2H, NH2),
2.79–2.81 (m, 1H, CH), 1.19 (d, J= 7.6 Hz, 6H, (CH3)2);
13C NMR (100 MHz, DMSO-d6): d 171.2, 162.7, 159.3,
155.4, 154.2, 153.1, 151.7, 151.1, 147.1, 135.3, 134.6, 133.1,
131.8, 130.4, 129.5, 129.3, 127.5, 126.3, 125.7, 122.8, 122.3,
119.1, 109.2, 39.3, 21.4; LCMS: (m/z) 565 ((M)+, 100%). Anal.
Calcd. for C30H24ClN7OS: C, 69.83; H, 6.89; N, 9.58. Found:
C, 69.91; H, 6.78; N, 9.49.
Synthesis, antibacterial and antifungal activity of novel benzothiazole pyrimidine derivatives 6875. Conclusion
In conclusion, we have described a simple and efﬁcient
protocol for the synthesis of novel benzothiazole pyrimidine
derivatives (7a–k) with good yields. The antibacterial and
antifungal activities of all the synthesized compounds were
investigated. It is evident that newly synthesized compounds,
7b, 7e, 7f, 7g, 7h and 7j have excellent antibacterial and anti-
fungal activities. For the above compounds a signiﬁcant
improvement in their antibacterial and anti fungal activities
has been examined over the earlier reported compounds
(Maddila et al., 2011). These novel class of new benzothiazole
pyrimidine derivatives reported have a probability to emerge
as a valuable lead series with great potential to be used as anti-
bacterial and antifungal agents, and as promising candidates
for further efﬁcacy evaluation.Acknowledgements
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